{"id":"403d1d53-eceb-5431-aafc-b271626783d2","stable_key":"a9dd23c6-978a-5755-8bd8-f29bd1fe0cda:nia-clin-ontrans-skin","predicate":"does_not_reduce_in_tested_population","statement":"ONTRANS recorded 207 versus 210 new keratinocyte cancers with nicotinamide and placebo: rate ratio 1.0, 95% CI 0.8–1.3.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"c251e86d-75b3-5555-8c4d-468918eca465","mechanism_event_label":"The same daily amount did not show a skin-cancer reduction in this smaller transplant-recipient trial.","subject":{"id":"08c27a3f-552e-5c92-8688-321a9b64a0d6","slug":"nicotinamide","display_name":"Nicotinamide","entity_type_key":"small_molecule"},"object":{"id":"dba69dcc-f75e-5775-8132-a9735e5d821f","slug":"nonmelanoma-skin-cancer-incidence","display_name":"New keratinocyte skin cancer incidence","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"c251e86d-75b3-5555-8c4d-468918eca465","stable_key":"a9dd23c6-978a-5755-8bd8-f29bd1fe0cda:nia-clin-ontrans-skin-event","event_type":"observed_intervention","label":"The same daily amount did not show a skin-cancer reduction in this smaller transplant-recipient trial.","description":"ONTRANS recorded 207 versus 210 new keratinocyte cancers with nicotinamide and placebo: rate ratio 1.0, 95% CI 0.8–1.3.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"08c27a3f-552e-5c92-8688-321a9b64a0d6","slug":"nicotinamide","display_name":"Nicotinamide","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"dba69dcc-f75e-5775-8132-a9735e5d821f","slug":"nonmelanoma-skin-cancer-incidence","display_name":"New keratinocyte skin cancer incidence","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"cross_nutrient","value_text":"Niacin precursor form and the measured endpoint are separate graph entities.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/niacin-clinical-sources/allen2023.abstract.txt\", \"locator\": \"Indexed primary abstract\", \"file_sha256\": \"0331a413552524d52730cd68ea35a70b589a37aa0a29d25bbc7b6f4777dbdcbd\", \"start_char\": 0, \"end_char\": 2229, \"text_sha256\": \"0331a413552524d52730cd68ea35a70b589a37aa0a29d25bbc7b6f4777dbdcbd\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"ONTRANS double-blind randomized trial; 158 solid-organ transplant recipients with recurrent keratinocyte cancers","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Nicotinamide 500 mg twice daily versus placebo for 12 months","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Trial stopped early because of poor recruitment. Population differs materially from immunocompetent ONTRAC participants; neither the population difference nor different statistical results alone constitutes a research contradiction.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Niacin research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"niacin","display_name":"Niacin (vitamin B3)","entity_type_key":"nutrient_element"}},{"dimension":"organism","value_text":"Homo sapiens","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The same daily amount did not show a skin-cancer reduction in this smaller transplant-recipient trial.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[nia-clin-allen2023] Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients. (2023). https://pubmed.ncbi.nlm.nih.gov/36856616/ DOI: 10.1056/nejmoa2203086","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Skin cancer counts","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"e47143f2-6e48-5862-ac80-fecba50fb611","evidence_kind":"source_excerpt","locator":"Lines 1445-1457","start_line":1445,"end_line":1457,"excerpt":"### nia-clin-ontrans-skin\nONTRANS recorded 207 versus 210 new keratinocyte cancers with nicotinamide and placebo: rate ratio 1.0, 95% CI 0.8–1.3.\nCondition category: normal\nnutrient_topic: Niacin research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: The same daily amount did not show a skin-cancer reduction in this smaller transplant-recipient trial.\norganism: Homo sapiens\ntissue_or_cell_type: Skin cancer counts\nexperimental_model: ONTRANS double-blind randomized trial; 158 solid-organ transplant recipients with recurrent keratinocyte cancers\nlimitations: Trial stopped early because of poor recruitment. Population differs materially from immunocompetent ONTRAC participants; neither the population difference nor different statistical results alone constitutes a research contradiction.\nexposure: Nicotinamide 500 mg twice daily versus placebo for 12 months\ncross_nutrient: Niacin precursor form and the measured endpoint are separate graph entities.\nevidence_span: {\"source_cache\": \"artifacts/niacin-clinical-sources/allen2023.abstract.txt\", \"locator\": \"Indexed primary abstract\", \"file_sha256\": \"0331a413552524d52730cd68ea35a70b589a37aa0a29d25bbc7b6f4777dbdcbd\", \"start_char\": 0, \"end_char\": 2229, \"text_sha256\": \"0331a413552524d52730cd68ea35a70b589a37aa0a29d25bbc7b6f4777dbdcbd\"}\n[nia-clin-allen2023] Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients. (2023). https://pubmed.ncbi.nlm.nih.gov/36856616/ DOI: 10.1056/nejmoa2203086","model_system":"ONTRANS double-blind randomized trial; 158 solid-organ transplant recipients with recurrent keratinocyte cancers","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [nia-clin-allen2023] Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients. (2023). https://pubmed.ncbi.nlm.nih.gov/36856616/ DOI: 10.1056/nejmoa2203086","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"a62b7b5b-786a-57e9-85e9-67c6912a5054","stable_key":"import-a9dd23c6-978a-5755-8bd8-f29bd1fe0cda","title":"Niacin: NAD metabolism, deficiency and nutrient interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"a8cac59639322f74812ce12eef338c2f6c385c04cc4af6ab511fc7c972f0c2e6","revision_id":"bec8fc45-12e7-5f75-a814-5d72ed015d01","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}